Tracking infections and securing supply chains: The race against a virus
As the SARS-CoV-2 virus forced the world into lockdown, researchers in many places began working at top speed. The development and production of PCR tests for identifying active infections became the main task of many medical technology companies. Making these tests available everywhere under the most difficult conditions posed a very unique challenge.
A tale of two cities
Marburg is a well-established factory with all the equipment we needed. So we worked with the team there to produce more tests.
Michael Schleichert, Managing Director and Head of Research & Development at Fast Track Diagnostics, Esch-sur-Alzette, Luxembourg
Trust and reliability are the key
Mass production in record time
Within four weeks, we had obtained three key authorizations we needed to supply our tests worldwide: CE marking for the European market, Emergency Use Authorization (EUA) by the US Food and Drug Administration for the US market, and Emergency Use Listing (EUL) by the World Health Organization for international distribution. We knew we could do it.
Mirza Kokic, Head of Quality Management and Regulatory Affairs, Fast Track Diagnostics, Esch-sur-Alzette, Luxembourg
A new normal
Precision pays off
Our test is currently one of the five most sensitive tests available1 – so the effort was definitely worth it.
Mirza Kokic, Head of Quality Management and Regulatory Affairs, Fast Track Diagnostics, Esch-sur-Alzette, Luxembourg
